Healthcare Professionals

OptiSphere Embolization Spheres

Hypervascular Tumor Embolization

  

RESORBABILITY MEETS RELIABILITY

Experience reliable hypervascular tumor embolization with the benefit of resorbable spheres. OptiSphere™ offers patients an alternative embolic option. Traditional options for embolizing hypervascular tumors leave behind implants. OptiSphere embolization spheres begin to degrade starting at four weeks post-procedure, with significant degradation noted at nine weeks.1


PRODUCT DETAILS

OptiSphere is made from purified porcine skin gelatin, an embolic material that has been used for more than 40 years.2 The product is crosslinked with glutaraldehyde, which improves the mechanical strength of the spheres and provides controlled degradation after implant. The spherical shape provides smooth embolic delivery and even, predictable distribution. Spheres are offered in two volume options and five size ranges and are designed for reliable, targeted embolization of hypervascular tumors.

Multicolored syringes containing Medtronic OptiSphere embolization spheres arranged in an arc

BACKED BY MEDTRONIC

Medtronic is the world’s largest medical technology company, founded in 1949 and committed to quality, reliability, and supporting you at every step with:

  • Technical support
  • Procedural assistance
  • Reimbursement and coverage
  • Product compatibility
  • Clinical and healthcare economic evidence
  • Dedicated representatives

INDICATIONS AND RISKS

OptiSphere is intended for the embolization of hypervascular tumors. Risks of embolization procedures may include non-target embolization and post-embolization syndrome; please refer to the Indications, Safety, and Warnings for a full listing of the indications, contraindications, warnings, precautions, and potential adverse effects.


CONTACT US

Interested in hearing more about OptiSphere embolization spheres? Fill out the form below to have your Medtronic Sales Representative contact you.

Mandatory fields are marked with an *



1

Data on file based on animal testing. Pre-clinical studies are not indicative of human clinical outcomes.

2

Tadavarthy SM, Knight L, Ovitt TW, Snyder C, Amplatz K. Therapeutic transcatheter arterial embolization. Radiology. 1974;112(1):13-6.